Literature DB >> 10848604

Conservation and function of a potential substrate-binding domain in the yeast Clb5 B-type cyclin.

F R Cross1, M D Jacobson.   

Abstract

Cyclin A contains a region implicated in binding to the p27 inhibitor and to substrates. There is strong evolutionary conservation of surface residues contributing to this region in many cyclins, including yeast B-type cyclins, despite the absence of a yeast p27 homolog. The yeast S-phase B-type cyclin Clb5p interacted with mammalian p27 in a two-hybrid assay. This interaction was disrupted by mutations designed to disrupt hydrophobic interactions (hpm mutation) or hydrogen bonding (Q241A mutation) based on the cyclin A-p27 crystal structure. In contrast, mutation of the Clb5p p27-binding domain only slightly reduced binding and inhibition by the Sic1p Clb-Cdc28p kinase inhibitor. Mutations disrupting the p27-binding domain strongly reduced Clb5p biological activity in diverse assays without reducing Clb5p-associated kinase activity. An analogous hpm mutation in the mitotic cyclin Clb2p reduced mitotic function, but in some assays this mutation increased the ability of Clb2p to perform functions normally restricted to Clb5p. These results support the idea of a modular, structurally conserved cyclin domain involved in substrate targeting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848604      PMCID: PMC85916          DOI: 10.1128/MCB.20.13.4782-4790.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

2.  p21CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases.

Authors:  P Saha; Q Eichbaum; E D Silberman; B J Mayer; A Dutta
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

3.  SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities.

Authors:  R Verma; R M Feldman; R J Deshaies
Journal:  Mol Biol Cell       Date:  1997-08       Impact factor: 4.138

4.  Cdc20 is essential for the cyclosome-mediated proteolysis of both Pds1 and Clb2 during M phase in budding yeast.

Authors:  H H Lim; P Y Goh; U Surana
Journal:  Curr Biol       Date:  1998-02-12       Impact factor: 10.834

5.  Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.

Authors:  B A Schulman; D L Lindstrom; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

6.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

7.  CLB5: a novel B cyclin from budding yeast with a role in S phase.

Authors:  C B Epstein; F R Cross
Journal:  Genes Dev       Date:  1992-09       Impact factor: 11.361

8.  The B-type cyclin kinase inhibitor p40SIC1 controls the G1 to S transition in S. cerevisiae.

Authors:  E Schwob; T Böhm; M D Mendenhall; K Nasmyth
Journal:  Cell       Date:  1994-10-21       Impact factor: 41.582

9.  p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.

Authors:  L Zhu; E Harlow; B D Dynlacht
Journal:  Genes Dev       Date:  1995-07-15       Impact factor: 11.361

10.  Destruction of the CDC28/CLB mitotic kinase is not required for the metaphase to anaphase transition in budding yeast.

Authors:  U Surana; A Amon; C Dowzer; J McGrew; B Byers; K Nasmyth
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  29 in total

1.  Testing cyclin specificity in the exit from mitosis.

Authors:  M D Jacobson; S Gray; M Yuste-Rojas; F R Cross
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  Testing a mathematical model of the yeast cell cycle.

Authors:  Frederick R Cross; Vincent Archambault; Mary Miller; Martha Klovstad
Journal:  Mol Biol Cell       Date:  2002-01       Impact factor: 4.138

3.  Interaction of the S-phase cyclin Clb5 with an "RXL" docking sequence in the initiator protein Orc6 provides an origin-localized replication control switch.

Authors:  Gwendolyn M Wilmes; Vincent Archambault; Richard J Austin; Matthew D Jacobson; Stephen P Bell; Frederick R Cross
Journal:  Genes Dev       Date:  2004-04-22       Impact factor: 11.361

4.  Novel role for Cdc14 sequestration: Cdc14 dephosphorylates factors that promote DNA replication.

Authors:  Joanna Bloom; Frederick R Cross
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

5.  G1 cyclin driven DNA replication.

Authors:  Roger Palou; Asrar Malik; Gloria Palou; Fanli Zeng; Ping Ren; David G Quintana
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Among B-type cyclins only CLB5 and CLB6 promote premeiotic S phase in Saccharomyces cerevisiae.

Authors:  James M DeCesare; David T Stuart
Journal:  Genetics       Date:  2011-12-29       Impact factor: 4.562

7.  Cyclin-cyclin-dependent kinase regulatory response is linked to substrate recognition.

Authors:  Maria Emanuela Cuomo; Georgina M Platt; Laurence H Pearl; Sibylle Mittnacht
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

8.  The schedule of destruction of three mitotic cyclins can dictate the timing of events during exit from mitosis.

Authors:  D H Parry; P H O'Farrell
Journal:  Curr Biol       Date:  2001-05-01       Impact factor: 10.834

9.  Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis.

Authors:  Anna M Bentley; Guillaume Normand; Jonathan Hoyt; Randall W King
Journal:  Mol Biol Cell       Date:  2007-09-19       Impact factor: 4.138

10.  Clb6/Cdc28 and Cdc14 regulate phosphorylation status and cellular localization of Swi6.

Authors:  Marco Geymonat; Ad Spanos; Glenn P Wells; Stephen J Smerdon; Steven G Sedgwick
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.